- Home
- KFS vs RCKT Comparison
KFS vs RCKT Comparison
Compare KFS & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KFS
- RCKT
- Stock Information
- Founded
- KFS 1989
- RCKT 1999
- Country
- KFS United States
- RCKT United States
- Employees
- KFS N/A
- RCKT N/A
- Industry
- KFS Property-Casualty Insurers
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- KFS Finance
- RCKT Health Care
- Exchange
- KFS Nasdaq
- RCKT Nasdaq
- Market Cap
- KFS 417.8M
- RCKT 328.6M
- IPO Year
- KFS 1996
- RCKT N/A
- Fundamental
- Price
- KFS $14.37
- RCKT $3.28
- Analyst Decision
- KFS
- RCKT Buy
- Analyst Count
- KFS 0
- RCKT 13
- Target Price
- KFS N/A
- RCKT $12.96
- AVG Volume (30 Days)
- KFS 69.0K
- RCKT 6.0M
- Earning Date
- KFS 08-07-2025
- RCKT 08-07-2025
- Dividend Yield
- KFS N/A
- RCKT N/A
- EPS Growth
- KFS N/A
- RCKT N/A
- EPS
- KFS N/A
- RCKT N/A
- Revenue
- KFS $119,287,000.00
- RCKT N/A
- Revenue This Year
- KFS N/A
- RCKT N/A
- Revenue Next Year
- KFS N/A
- RCKT $108.43
- P/E Ratio
- KFS N/A
- RCKT N/A
- Revenue Growth
- KFS 12.05
- RCKT N/A
- 52 Week Low
- KFS $7.06
- RCKT $2.19
- 52 Week High
- KFS $16.80
- RCKT $22.01
- Technical
- Relative Strength Index (RSI)
- KFS 54.71
- RCKT 51.17
- Support Level
- KFS $13.96
- RCKT $2.88
- Resistance Level
- KFS $14.36
- RCKT $3.74
- Average True Range (ATR)
- KFS 0.38
- RCKT 0.27
- MACD
- KFS 0.05
- RCKT 0.02
- Stochastic Oscillator
- KFS 89.60
- RCKT 35.43
About KFS Kingsway Financial Services Inc. (DE)
Kingsway Financial Services Inc through subsidiaries operates in the extended warranty and business services industries in the United States. The company operates through segments namely, Extended Warranty and Kingsway Search Xcelerator. The Extended Warranty segment provides after-market vehicle protection services distributed by credit unions. The firm generates maximum revenue from the Extended Warranty segment in the form of Service fee and commission income.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.